gefitinib

Drug Overview:

Gefitinib is an oral, first-generation tyrosine kinase inhibitor (TKI) that selectively targets the epidermal growth factor receptor (EGFR). It was one of the first targeted therapies developed for non-small cell lung cancer (NSCLC) and revolutionized treatment for patients with specific EGFR mutations.

• Generic Name: Gefitinib
• US Brand Name: Iressa®
• Drug Class: Tyrosine Kinase Inhibitor (Targeted Therapy)
• Route of Administration: Oral (tablet)
• FDA Approval Status: Approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

gefitinib shows incredible progress in treating lung cancer. Learn how this powerful targeted therapy improves survival rates fast.

What Is It and How Does It Work? (Mechanism of Action):

Gefitinib is a targeted therapy that works by specifically inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), a key driver of cancer cell growth and survival in a subset of NSCLC.

• Molecular Target: Gefitinib is a reversible, competitive inhibitor of the ATP-binding site of the EGFR tyrosine kinase domain.
• Cellular Impact: In NSCLC tumors with activating EGFR mutations (exon 19 deletion or L858R), the receptor is constitutively active, sending continuous pro-growth and pro-survival signals via downstream pathways like RAS-RAF-MAPK and PI3K-AKT-mTOR. By binding to the ATP pocket, gefitinib blocks receptor autophosphorylation and activation.
• Result: Inhibition of these critical signaling cascades leads to cell cycle arrest, induction of apoptosis (programmed cell death), and inhibition of angiogenesis (new blood vessel formation). This results in significant tumor shrinkage and disease control in tumors dependent on mutated EGFR signaling.
• Targeted Therapy Characteristic: As an EGFR tyrosine kinase inhibitor, gefitinib is a “smart drug” or targeted therapy. It represents a paradigm shift from non-selective chemotherapy to treatment based on the specific molecular characteristics of a patient’s tumor.

FDA Approved Clinical Indications:

• Oncological Uses:
  • Non-Small Cell Lung Cancer (NSCLC): First-line treatment of metastatic NSCLC in patients whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
• Non-Oncological Uses:
  • There are currently no FDA-approved non-oncological indications for gefitinib.

Dosage and Administration Protocols:

Gefitinib is administered orally once daily. Consistent, uninterrupted dosing is required to maintain therapeutic levels.

Renal and Hepatic Dose Adjustments

• Renal Impairment: No initial dose adjustment is required for patients with mild to severe renal impairment.
• Hepatic Impairment: Dose reduction is necessary for patients with moderate to severe hepatic impairment (Child-Pugh Class B or C) due to the drug’s metabolism by the liver. Close monitoring for adverse effects is mandatory.
• Drug Interactions: Due to its metabolism by CYP3A4, co-administration with strong CYP3A4 inducers (e.g., Rifampin) can drastically reduce Gefitinib levels, requiring dose adjustments or alternative agents.

Clinical Efficacy and Research Results:

Gefitinib’s efficacy in EGFR-mutant NSCLC was established in the landmark IPASS trial and confirmed in subsequent studies. While newer generation TKIs (e.g., osimertinib) are now preferred first-line agents, gefitinib remains an important part of the treatment landscape.

• Progression-Free Survival (PFS): In the IPASS trial, gefitinib demonstrated a significantly longer median PFS of 9.5 months compared to 6.3 months with carboplatin/paclitaxel chemotherapy in patients with EGFR-mutant NSCLC.
• Objective Response Rate (ORR): Gefitinib achieves high objective response rates, typically around 70-80% in treatment-naïve EGFR-mutant patients, compared to approximately 30-40% with chemotherapy.
• Contemporary Context (2020-2025): Osimertinib, a third-generation EGFR TKI, is now the preferred first-line therapy due to superior PFS and CNS activity. However, gefitinib is still used in specific geographical regions due to cost and access. Research focuses on understanding and overcoming resistance mechanisms to first-generation TKIs like gefitinib.

Safety Profile and Side Effects:

Black Box Warning:

• Interstitial Lung Disease (ILD): Gefitinib can cause severe, sometimes fatal, ILD/pneumonitis. Incidence is higher in Asian populations. Treatment should be interrupted and discontinued for confirmed ILD.

Common Side Effects (>20%):

• Dermatological: Skin rash (acneiform, papulopustular), dry skin, pruritus (itching).
• Gastrointestinal: Diarrhea (may be severe), nausea, vomiting, anorexia, stomatitis.
• Hepatic: Elevated liver enzymes (AST, ALT).
• Ocular: Conjunctivitis, blepharitis, dry eyes.
• Constitutional: Fatigue, weakness.

Management Strategies:

• Interstitial Lung Disease (ILD): Immediate interruption of therapy upon presentation of new/worsening respiratory symptoms (dyspnea, cough, fever). Permanently discontinue for confirmed ILD.
• Diarrhea: Manage promptly with antidiarrheal agents (e.g., loperamide). Ensure adequate hydration. For severe diarrhea (Grade ≥3), interrupt therapy and resume at a reduced dose upon recovery.
• Skin Rash: Use moisturizers, topical steroids (e.g., hydrocortisone, clindamycin), and oral antibiotics (e.g., minocycline, doxycycline) for moderate to severe rash. Avoid sun exposure.
• Hepatotoxicity: Monitor liver function tests periodically. Interrupt and dose reduce for severe elevations.

Serious Adverse Events

• Severe Interstitial Lung Disease (ILD)/Pneumonitis.
• Severe Hepatotoxicity.
• Gastrointestinal Perforation.
• Severe Diarrhea with dehydration and electrolyte imbalance.
• Corneal Erosion/Ulceration.
• Hemorrhage (e.g., cerebral hemorrhage, hemoptysis).

Research Areas:

Research involving gefitinib is now primarily focused on understanding and combating resistance. Current investigations (2020-2025) explore:

1. Combination Therapies: Studying gefitinib in combination with chemotherapy, anti-angiogenic agents (e.g., bevacizumab), or other targeted therapies to delay the emergence of resistance.
2. Overcoming Resistance: Investigating the mechanisms of acquired resistance (e.g., T790M mutation, MET amplification) and strategies to overcome them, often by sequencing or combining with newer-generation TKIs.
3. Adjuvant Therapy: Evaluating its use after surgery (adjuvant) for early-stage EGFR-mutant NSCLC to prevent recurrence.

Patient Management & Practical Recommendations:

Pre-treatment Tests:

• EGFR Mutation Testing: Mandatory. Tumor tissue or liquid biopsy must confirm the presence of an EGFR exon 19 deletion or exon 21 (L858R) mutation.
• Liver Function Tests (LFTs).
• Pregnancy Test for women of childbearing potential.
• Baseline Pulmonary Assessment.

Precautions During Treatment:

• Pulmonary Monitoring: Patients must be educated to report any new or worsening cough, shortness of breath, or fever immediately.
• Diarrhea Management: Have a plan for immediate loperamide use.
• Skin Care: Initiate prophylactic skin care with moisturizers and avoid sun exposure.
• Ocular Symptoms: Report eye pain, redness, or vision changes.
• Drug Interactions: Avoid concomitant use of strong CYP3A4 inducers (e.g., rifampin, phenytoin) as they can decrease gefitinib levels. Use caution with strong CYP3A4 inhibitors (e.g., ketoconazole).

Do’s and Don’ts:

• DO take your medication once daily at the same time each day.
• DO report any new cough, shortness of breath, severe diarrhea, or worsening skin rash immediately.
• DO use sunscreen and moisturize your skin regularly.
• DON’T stop taking gefitinib without consulting your oncologist, even if you feel well.
• DON’T take over-the-counter antacids (containing aluminum, magnesium) within 6 hours of taking gefitinib, as they can reduce its absorption.
• DON’T become pregnant or father a child while on this medication and for at least 2 weeks after the last dose.

Legal Disclaimer:

This guide is for informational purposes for patients and healthcare professionals. It summarizes the FDA-approved use and key risks of gefitinib and is not a substitute for professional medical advice. Treatment decisions are highly individualized and depend on specific molecular testing. Always consult your qualified healthcare provider for advice on your specific condition and treatment.